MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Celldex Therapeutics Accounts Payables 2011-2026 | CLDX
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Celldex Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.26 M | 3.49 M | 3.34 M | 1.23 M | 1.05 M | 1.17 M | 1.07 M | 1.72 M | 1.74 M | 1.51 M | 2.6 M | 2.24 M | 745 K | 935 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.49 M | 745 K | 1.86 M |
Quarterly Accounts Payables Celldex Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.27 M | 2.07 M | 3.41 M | 3.26 M | 1.11 M | 3.8 M | 3.23 M | 3.49 M | 3.59 M | 881 K | 3.37 M | 3.34 M | 2.27 M | 902 K | 1.02 M | 1.23 M | 836 K | 685 K | 997 K | 1.05 M | 1.05 M | 1.05 M | 1.05 M | 1.17 M | 1.17 M | 1.17 M | 1.17 M | 1.07 M | 1.07 M | 1.07 M | 1.07 M | 1.72 M | 1.72 M | 1.72 M | 1.72 M | 1.74 M | 1.74 M | 1.74 M | 1.74 M | 1.51 M | 1.51 M | 1.51 M | 1.51 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.24 M | 2.24 M | 2.24 M | 2.24 M | 745 K | 745 K | 745 K | 745 K | 935 K | 935 K | 935 K | 935 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.27 M | 685 K | 1.74 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Biogen
BIIB
|
424 M | $ 173.17 | 0.92 % | $ 25.2 B |  USA |
 |
Adagene
ADAG
|
4.24 M | $ 2.4 | -3.61 % | $ 135 M |  China |
 |
Acorda Therapeutics
ACOR
|
13.4 M | - | -24.86 % | $ 820 K | USA |
 |
Aptorum Group Limited
APM
|
3.24 M | $ 0.98 | 1.35 % | $ 5.34 M | China |
 |
Catalyst Biosciences
CBIO
|
355 K | $ 11.66 | -8.95 % | $ 768 M | USA |
 |
Akero Therapeutics
AKRO
|
9.03 M | - | - | $ 3.67 B | USA |
 |
BioXcel Therapeutics
BTAI
|
16 M | $ 1.77 | -2.75 % | $ 4.49 M | USA |
 |
Applied Molecular Transport
AMTI
|
1.58 M | - | - | $ 10.1 M | USA |
 |
ARCA biopharma
ABIO
|
3.46 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
601 K | - | 4.01 % | $ 150 M |  Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
17.7 M | $ 67.41 | 0.54 % | $ 9.02 B | USA |
 |
Compugen Ltd.
CGEN
|
1.84 M | $ 2.04 | -2.39 % | $ 183 M |  Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
561 K | $ 4.36 | -2.46 % | $ 9.49 B | Israel |
 |
AgeX Therapeutics
AGE
|
1.41 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
677 K | - | - | $ 1.01 B | USA |
 |
Akouos
AKUS
|
1.28 M | - | 0.23 % | $ 488 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
8.13 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
30.5 M | $ 26.57 | 2.51 % | $ 1.29 B | USA |
 |
Coherus BioSciences
CHRS
|
35.2 M | $ 2.26 | 9.7 % | $ 213 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
153 M | $ 13.59 | 1.46 % | $ 4.2 B | USA |
 |
Albireo Pharma
ALBO
|
6.52 M | - | -0.23 % | $ 916 M | USA |
 |
Aptose Biosciences
APTO
|
1.26 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Acer Therapeutics
ACER
|
3.81 M | - | 2.71 % | $ 14 M | USA |
 |
Aravive
ARAV
|
8.76 M | - | -13.39 % | $ 1.45 M | USA |
 |
Alpine Immune Sciences
ALPN
|
4.29 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
247 K | - | 4.14 % | $ 49.1 M | USA |
 |
Athira Pharma
ATHA
|
319 K | - | - | $ 269 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
750 K | - | -11.43 % | $ 502 K | USA |
 |
AVROBIO
AVRO
|
27 K | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
4.08 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
10.6 M | $ 2.75 | 1.85 % | $ 17.3 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
13.3 M | - | -6.81 % | $ 3.04 B | USA |
 |
Brickell Biotech
BBI
|
406 K | - | -5.38 % | $ 6.06 M | USA |